Udenafil - CAS 268203-93-6
Catalog number: 268203-93-6
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C25H36N6O4S
Molecular Weight:
516.66
COA:
Inquire
Targets:
Phosphodiesterase (PDE)
Description:
Udenafil is an oral PDE5 inhibitor. Udenafil significantly increased cAMP and cGMP levels and were more highly distributed in the prostate than plasma. The T/P ratio of udenafil was higher than tadalafil. These findings may help in the assessment of the feasibility of using PDE5 Is to concurrently treat both LUTS and erectile dysfunction. After 12 weeks of treatment, the patients treated with udenafil showed significantly greater change from baseline in the IIEF-EF domain score compared with placebo (placebo, 0.20; 100-mg udenafil, 7.52; and 200-mg udenafil, 9.93, respectively) (P < 0.0001). udenafil significantly enhanced the rates of successful penetration (SEP Q2) and maintenance of erection (SEP Q3) (P < 0.0001).
Purity:
>98%
Synonyms:
DA-8159, DA 8159, DA8159, Udenafil, Zydena
MSDS:
Inquire
InChIKey:
IYFNEFQTYQPVOC-UHFFFAOYSA-N
InChI:
InChI=1S/C25H36N6O4S/c1-5-8-20-22-23(31(4)29-20)25(32)28-24(27-22)19-16-18(10-11-21(19)35-15-6-2)36(33,34)26-13-12-17-9-7-14-30(17)3/h10-11,16-17,26H,5-9,12-15H2,1-4H3,(H,27,28,32)
Canonical SMILES:
CCCC1=NN(C2=C1NC(=NC2=O)C3=C(C=CC(=C3)S(=O)(=O)NCCC4CCCN4C)OCCC)C
1.Protective effects of udenafil citrate, piracetam and dexmedetomidine treatment on testicular torsion/detorsion-induced ischaemia/reperfusion injury in rats.
Tuglu D1, Yuvanc E1, Ozan T2, Bal F1, Yilmaz E1, Atasoy P3, Kisa U4, Batislam E1. Andrologia. 2015 Nov 20. doi: 10.1111/and.12499. [Epub ahead of print]
The aim of this study was to investigate the antioxidant properties of udenafil citrate (1.4 mg kg-1 -2.8 mg kg-1 ), dexmedetomidine 25 μg kg-1 and piracetam 200 mg kg-1 administered on ipsilateral/contralateral testes after ischaemia in a rat model of testicular torsion/detorsion (T/D) and define its protective effect histologically. Fifty-six Wistar albino rats were included and randomly assigned into 6 groups. No intervention was performed in control group (Group 1, n = 8) and in torsion/detorsion group, (Group 2, n = 8). Udenafil 1.4 mg kg-1 was given to torsion/detorsion group (Group 3, n = 10), udenafil 2.8 mg kg-1 was given to torsion/detorsion group (Group 4, n = 10), piracetam 200 mg kg-1 was given to torsion/detorsion group (Group 5, n = 10) and dexmedetomidine 25 μg kg-1 was given to torsion/detorsion group (Group 6, n = 10) intraperitoneally after 60 mins of testicular torsion. Biochemical and histopathological testicular injury were evaluated.
2.The Effect of Age on the Pharmacokinetics of Udenafil in Healthy Subjects.
Choi HK1, Jung JA1,2, Bahng MY3, Cho DY4, Yeo CW1,2, Kim EY1,2, Shin JG1,2. J Clin Pharmacol. 2016 Mar 23. doi: 10.1002/jcph.739. [Epub ahead of print]
Udenafil, a cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5) inhibitor, has been developed to treat erectile dysfunction. We evaluated the effect of age on the pharmacokinetics and tolerability of udenafil. A single-center, open-label, parallel-group phase 1 study was conducted in healthy adult subjects who took a single oral dose of udenafil (100 mg). The pharmacokinetics and tolerability of udenafil were compared between 12 healthy young males (21-27 years) and 12 healthy elderly males (65-78 years). Serial blood and urine samples were collected for up to 60 h and 48 h after dosing. The plasma concentrations of udenafil and its major metabolite, DA-8164, were analysed using a validated liquid chromatography-tandem mass spectrometry method. The mean Cmax of udenafil tended to be slightly less (214.0 vs. 292.8 μg/L) in the elderly compared with the young (GMR: 68.9, 95% CI: 48.9-97.1); however, the AUC did not differ between the groups (1858.
3.Oral udenafil and aceclofenac for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis in high-risk patients: a randomized multicenter study.
Lee TY1, Choi JS2, Oh HC3, Song TJ4, Do JH3, Cheon YK1. Korean J Intern Med. 2015 Sep;30(5):602-9. doi: 10.3904/kjim.2015.30.5.602. Epub 2015 Aug 27.
BACKGROUND/AIMS: Acute pancreatitis is a common complication of endoscopic retrograde cholangiopancreatography (ERCP). Combination therapy w ith ora l udenafil and aceclofenac may reduce the occurrence of post-ERCP pancreatitis by targeting different pathophysiological mechanisms. We investigated whether combining udenafil and aceclofenac reduced the rates of post-ERCP pancreatitis.
4.An Observational Study to Evaluate the Prevalence of Erectile Dysfunction (ED) and Prescribing Pattern of Drugs in Patients with ED Visiting an Andrology Specialty Clinic, Mumbai: 2012-14.
Mutha AS1, Kulkarni VR2, Bhagat SB3, Beldar AS1, Patel SB4. J Clin Diagn Res. 2015 Jul;9(7):PC08-11. doi: 10.7860/JCDR/2015/14520.6174. Epub 2015 Jul 1.
INTRODUCTION: Erectile dysfunction (ED) is a common occurrence and its incidence is expected to increase significantly along with the increase in various lifestyle diseases. The drug utilization for ED is very low. Also, studies describing the prescription pattern in ED are lacking.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Phosphodiesterase (PDE) Products


CAS 115344-47-3 Siguazodan

Siguazodan
(CAS: 115344-47-3)

Siguazodan is a selective phosphodiesterase 3 (PDE3) inhibitor (IC50 = 117 nM). Siguazodan acts as a potent vasodilator.

CAS 330784-47-9 Avanafil

Avanafil
(CAS: 330784-47-9)

A phosphodiesterase (PDE5) inhibitor, used to treat erectile dysfunction.

CAS 898563-00-3 TP-10

TP-10
(CAS: 898563-00-3)

TP-10 is a PDE10A inhibitor with IC50 of 0.8 nM. It has extremely potent PDE10A inhibitory activity and high selectivity against other PDEs. It is active in the...

CAS 334827-98-4 Gisadenafil besylate

Gisadenafil besylate
(CAS: 334827-98-4)

Gisadenafil besylate is a potent PDE5 inhibitor (IC50 = 1.23 nM) with >100-fold selectivity for PDE5 over PDE6. Gisadenafil besylate inhibits the breakdown of c...

CAS 1394033-54-5 PF 05180999

PF 05180999
(CAS: 1394033-54-5)

PF 05180999 is a potent and selective PDE2A inhibitor (IC50 = 1 nM), with 2000-fold selectivity for PDE2A over PDE10A. PF 05180999 was evaluated for schizophren...

CAS 439083-90-6 Bay 60-7550

Bay 60-7550
(CAS: 439083-90-6)

Bay 60-7550 is a potent PDE2 inhibitor. It is 50-fold more selective for PDE2 compared to PDE1 and greater than 100-fold selective compared to PDE5 PDE3B, PDE4B...

CAS 6493-05-6 Pentoxifylline

Pentoxifylline
(CAS: 6493-05-6)

Pentoxifylline is a competitive nonselective phosphodiesterase inhibitor which raises intracellular cAMP, activates PKA, inhibits TNF and leukotriene synthesis,...

CAS 1082743-70-1 PDE-9 inhibitor

PDE-9 inhibitor
(CAS: 1082743-70-1)

PDE-9 inhibitor is useful for neurodegenerative diseases.

Chemical Structure

CAS 268203-93-6 Udenafil

Quick Inquiry

Verification code

Featured Items